B
BenevolentAI
Creating Life-Changing Medicines with AI
London, UK (US presence)
350+
About BenevolentAI
Industry:
AI Drug Discovery
Founded:
2013
Founders:
Ken Sheridan, Jackie Hunter
Status:
Public (AMS: BAI)
Funding & Growth
Total Raised:
$500M+
Valuation:
$1B+
Stage:
Public
Key Investors:
Temasek
Woodford Investment
Lansdowne Partners
✓ Pros
- • Pioneer in AI drug discovery
- • Knowledge graph technology
- • AstraZeneca partnership
- • Good European work culture
- • Published research
✗ Cons
- • Stock volatility
- • UK-centric (limited US roles)
- • Pre-revenue drug discovery
- • Long timelines to validation